Dr. Roy Chuck Receives Publication Approvals for AmbioDry Research
COSTA MESA, California – 1 December 2004 – Roy Chuck, M.D. Ph.D. (IOP Medical Director) has recently received publication approvals for two research papers detailing the AmbioDry Amniotic Membrane technology.
“Biomechanical Characterization of Human Amniotic Membrane Preparations for Ocular Surface Reconstruction” (Ophthalmic Research) investigates the tensile and elastic properties of both frozen and dehydrated amniotic membrane technologies. The results detail the desirable elastic characteristics of low-dose, electron beam-irradiated amnion (AmbioDry™) – in comparison to the commercially-available frozen amnion.
“Staining Properties of De-Epithelialized Human Amniotic Membrane” (Cornea) evaluated the in vitro staining properties of de-epithelialized human amniotic membrane using five vital dyes. The study notes that the best candidates for the assistance of intra-operative visualization of de-epithelialized HAM are the higher concentration 1.0% fluorescein sodium and 0.5% lissamine green.
“Since its market introduction in November 2002, the AmbioDry technology has elevated surgical performance and outcomes for ocular surface reconstruction procedures”, states Erich Ziegler, Vice President. “Our focus in now on innovating surgical techniques and methods. Dr. Chuck’s clinical and research efforts are moving this pursuit forward.”
Roy S. Chuck M.D., Ph.D. is an Associate Professor of Ophthalmology at the Wilmer Eye Institute. A cornea specialist and board certified ophthalmologist, Dr.Chuck has expertise in the field of laser techniques for refractive eye problems and has published, patented and lectured extensively throughout his career. Dr. Chuck also has a strong research interest in ocular surface corneal transplantation and sight restoration.
Founded in 1988, IOP Ophthalmics develops and commercializes specialized, leading-edge surgical technologies for eye surgery. IOP’s purpose is to develop surgical solutions that improve the quality of life for patients, elevate the performance and productivity of eye care professionals, and lower costs to the provider.
IOP currently holds leadership positions with surgical devices for oculoplastic surgeries and bio-implant technologies for cornea, anterior and oculoplastic surgeries.
Media Contact: email@example.com